UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer

UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer

Abstract The androgen receptor (AR) is an attractive target for treating prostate cancer, considering its role in the development and progression of localized and metastatic prostate cancer. The high global mortality burden of prostate cancer, despite medical treatments such as androgen deprivation...

Full description

Bibliographic Details
Main Authors: Soohyun Lee, Hwa‐Ryeon Kim, Yaejin Woo, Jiyoung Kim, Han Wool Kim, Ji Youn Park, Beomseon Suh, Yuri Choi, Jungmin Ahn, Je Ho Ryu, Jae‐Seok Roe, Jaewhan Song, Song Hee Lee
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Advanced Science
Subjects:
androgen receptor
cancer therapy
degrader
prostate cancer
PROTAC
Online Access:https://doi.org/10.1002/advs.202400398

Internet

https://doi.org/10.1002/advs.202400398

Similar Items